Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:DVAX NASDAQ:LGND NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$39.94+4.9%$34.19$25.17▼$40.79$6.66B0.312.24 million shs2.91 million shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/ALGNDLigand Pharmaceuticals$234.66-0.5%$216.75$98.89▼$247.38$4.70B1.2223,616 shs126,406 shsRGENRepligen$122.73+8.4%$117.81$100.99▼$175.77$6.92B1.09965,959 shs1.60 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+1.98%+3.00%+13.10%+23.95%+27.39%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+58.49%LGNDLigand Pharmaceuticals+0.24%+8.33%-2.44%+20.25%+132.08%RGENRepligen-1.75%+1.28%-4.33%-15.32%-7.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$39.94+4.9%$34.19$25.17▼$40.79$6.66B0.312.24 million shs2.91 million shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/ALGNDLigand Pharmaceuticals$234.66-0.5%$216.75$98.89▼$247.38$4.70B1.2223,616 shs126,406 shsRGENRepligen$122.73+8.4%$117.81$100.99▼$175.77$6.92B1.09965,959 shs1.60 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+1.98%+3.00%+13.10%+23.95%+27.39%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+58.49%LGNDLigand Pharmaceuticals+0.24%+8.33%-2.44%+20.25%+132.08%RGENRepligen-1.75%+1.28%-4.33%-15.32%-7.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.76Moderate Buy$45.4012.02% UpsideDVAXDynavax Technologies 2.00Hold$32.00106.45% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.719.39% UpsideRGENRepligen 2.87Moderate Buy$166.1531.75% UpsideCurrent Analyst Ratings BreakdownLatest DVAX, RGEN, ALKS, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$160.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/13/2026ALKSAlkermes Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $48.005/11/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.005/7/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.005/6/2026RGENRepligen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $160.005/6/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$43.00 ➝ $44.005/6/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B4.32$1.82 per share22.31$10.51 per share3.86DVAXDynavax Technologies$330.51M5.51$0.16 per share97.88$4.54 per share3.41LGNDLigand Pharmaceuticals$274.48M17.20$7.86 per share29.97$49.76 per share4.73RGENRepligen$763.34M9.32$3.74 per share33.71$37.33 per share3.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9045.0373.69N/A9.78%9.26%5.66%7/28/2026 (Estimated)DVAXDynavax Technologies$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/ALGNDLigand Pharmaceuticals$124.45M$7.3731.9531.841.9055.95%16.19%11.13%8/6/2026 (Estimated)RGENRepligen$48.89M$0.90140.1351.692.226.73%4.88%3.48%8/4/2026 (Estimated)Latest DVAX, RGEN, ALKS, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70DVAXDynavax Technologies0.417.626.94LGNDLigand Pharmaceuticals0.4521.2820.95RGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%DVAXDynavax Technologies96.96%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%DVAXDynavax Technologies2.98%LGNDLigand Pharmaceuticals7.00%RGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableDVAXDynavax Technologies350117.43 million113.93 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableRGENRepligen2,00056.41 million56.07 millionOptionableDVAX, RGEN, ALKS, and LGND HeadlinesRecent News About These CompaniesRepligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/1006 minutes ago | gurufocus.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 27 at 2:16 AM | americanbankingnews.comGuggenheim Reaffirms Their Hold Rating on Repligen (RGEN)May 25 at 12:28 AM | theglobeandmail.comRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceMay 22, 2026 | globenewswire.comRepligen Announces Publication of the Company’s 2025 Corporate Sustainability ReportMay 20, 2026 | markets.businessinsider.comRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportMay 20, 2026 | globenewswire.comRepligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factorsMay 19, 2026 | quiverquant.comQQ1 rundown: Repligen (NASDAQ:RGEN) vs other drug development inputs & services stocksMay 19, 2026 | msn.comRepligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To KnowMay 17, 2026 | finance.yahoo.com1 growth stock with explosive upside and 2 facing headwindsMay 15, 2026 | msn.com5 Revealing Analyst Questions From Repligen’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comRepligen Shareholders Approve Directors, Auditor and Pay PlanMay 15, 2026 | tipranks.comRepligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comBarclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)May 11, 2026 | insidermonkey.comSwedbank AB Invests $4.15 Million in Repligen Corporation $RGENMay 10, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Repligen (RGEN) and IQVIA Holdings (IQV)May 7, 2026 | theglobeandmail.comRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare ConferenceMay 7, 2026 | globenewswire.comJPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $165.00May 6, 2026 | marketbeat.comRepligen's Q1 Earnings & Revenues Beat Estimates, Stock RisesMay 6, 2026 | zacks.comRepligen Corporation $RGEN Stock Position Decreased by UBS Group AGMay 6, 2026 | marketbeat.comRepligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift by end of 2027May 6, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026The Great Cloud Divide: How AI Is Reshuffling the Software DeckBy Jeffrey Neal Johnson | May 20, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026DVAX, RGEN, ALKS, and LGND Company DescriptionsAlkermes NASDAQ:ALKS$39.94 +1.85 (+4.86%) Closing price 04:00 PM EasternExtended Trading$39.62 -0.32 (-0.80%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Dynavax Technologies NASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Ligand Pharmaceuticals NASDAQ:LGND$234.66 -1.23 (-0.52%) Closing price 04:00 PM EasternExtended Trading$234.95 +0.29 (+0.13%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$122.73 +9.56 (+8.45%) Closing price 04:00 PM EasternExtended Trading$123.02 +0.29 (+0.24%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake and the Snowballing Impact of its AI Flywheel IREN Is Flipping the Switch from Bitcoin to AI 3 Stocks Rallying on Micron's Price Boost: Substance or Hype? This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It AI’s Biggest Bottleneck Could Make These 2 Stocks Soar If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
